Skip to main content
NCBI home page
British Medical Journal logoLink to British Medical Journal
. 1971 Apr 10;2(5753):73–77. doi: 10.1136/bmj.2.5753.73

Metabolic, Hormonal, and Vascular Changes after Synthetic Oestrogen Therapy in Oophorectomized Women

S Gow, I MacGillivray
PMCID: PMC1795534  PMID: 5551270

Abstract

Mestranol, the three-methyl ether form of ethinyloestradiol and one of the two oestrogens used in oral contraceptive steroids, was administered in a dose of 0·02 mg daily for 120 days to 25 oophorectomized women.

Urinary oestriol and pregnanediol excretions were unaffected by the mestranol treatment but there was a shift of the maturation index of the vaginal smear to the right, indicating a correction of the pretreatment oestrogen deficiency. No significant change in the blood pressure or electrocardiograph recordings occurred during this relatively short period of administration. A significant rise in the serum protein-bound iodine, which might be regarded as an undesirable effect of mestranol on a long-term basis, occurred. Hepatic function as measured by bromsulphthalein was not impaired by the treatment. Mestranol had no effect on the total body water or on the total exchangeable potassium of the women. Its two most serious adverse effects were impairment of glucose tolerance and a high incidence (16%) of venous thrombo-embolic disease.

The gravity of the adverse effects far outweighs any beneficial ones and precludes the use of mestranol alone for long-term hormone replacement therapy in postmenopausal women.

Full text

PDF
73

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALEXANDER R. W., MARMORSTON J. Effect of two synthetic estrogens on the level of serum protein-bound iodine in men and women with atherosclerotic heart disease. J Clin Endocrinol Metab. 1961 Mar;21:243–251. doi: 10.1210/jcem-21-3-243. [DOI] [PubMed] [Google Scholar]
  2. EISALO A., JAERVINEN P. A., LUUKKAINEN T. HEPATIC IMPAIRMENT DURING THE INTAKE OF CONTRACEPTIVE PILLS: CLINICAL TRIAL WITH POSTMENOPAUSAL WOMEN. Br Med J. 1964 Aug 15;2(5406):426–427. doi: 10.1136/bmj.2.5406.426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eisalo A., Heino A., Räsänen V. Oestrogen, proestogen and liver function tests. Acta Obstet Gynecol Scand. 1968;47(1):58–65. doi: 10.3109/00016346809157466. [DOI] [PubMed] [Google Scholar]
  4. Freston J. W., Englert E. The influence of age and excessive body weight on the distribution and metabolism of bromsulphalein. Clin Sci. 1967 Oct;33(2):301–312. [PubMed] [Google Scholar]
  5. GREENBLATT R. B. ESTROGEN THERAPY FOR POSTMENOPAUSAL FEMALES. N Engl J Med. 1965 Feb 11;272:305–308. doi: 10.1056/NEJM196502112720608. [DOI] [PubMed] [Google Scholar]
  6. Goldman J. A., Ovadia J. L. The effect of estrogen on intravenous glucose tolerance in woman. Am J Obstet Gynecol. 1969 Jan 15;103(2):172–178. doi: 10.1016/s0002-9378(16)34385-x. [DOI] [PubMed] [Google Scholar]
  7. HIGANO N., ROBINSON R. W., COHEN W. D. Increased incidence of cardiovascular disease in castrated women. Two-year follow-up studies. N Engl J Med. 1963 May 16;268:1123–1125. doi: 10.1056/NEJM196305162682007. [DOI] [PubMed] [Google Scholar]
  8. Inman W. H., Vessey M. P., Westerholm B., Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J. 1970 Apr 25;2(5703):203–209. doi: 10.1136/bmj.2.5703.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Javier Z., Gershberg H., Hulse M. Ovulatory suppressants, estrogens, and carbohydrate metabolism. Metabolism. 1968 May;17(5):443–456. doi: 10.1016/0026-0495(68)90067-x. [DOI] [PubMed] [Google Scholar]
  10. KLOPPER A., MICHIE E. A., BROWN J. B. A method for the determination of urinary pregnanediol. J Endocrinol. 1955 May;12(3):209–219. doi: 10.1677/joe.0.0120209. [DOI] [PubMed] [Google Scholar]
  11. Laragh J. H., Sealey J. E., Ledingham J. G., Newton M. A. Oral contraceptives. Renin, aldosterone, and high blood pressure. JAMA. 1967 Sep 18;201(12):918–922. doi: 10.1001/jama.201.12.918. [DOI] [PubMed] [Google Scholar]
  12. MACGILLIVRAY I., BUCHANAN T. J., BILLEWICZ W. Z. Values of total exchangeable sodium and potassium in normal females based on weight, height and age. Clin Sci. 1960 Feb;19:17–25. [PubMed] [Google Scholar]
  13. Nilsson I. M., Kullander S. Coagulation and fibrinolytic studies during use of gestagens. Acta Obstet Gynecol Scand. 1967;46(3):286–303. doi: 10.3109/00016346709158633. [DOI] [PubMed] [Google Scholar]
  14. Parrish H. M., Carr C. A., Hall D. G., King T. M. Time interval from castration in premenopausal women to development of excessive coronary atherosclerosis. Am J Obstet Gynecol. 1967 Sep 15;99(2):155–162. doi: 10.1016/0002-9378(67)90314-6. [DOI] [PubMed] [Google Scholar]
  15. Spellacy W. N., Carlson K. L. Plasma insulin and blood glucose levels in patients taking oral contraceptives. A preliminary report of a prospective study. Am J Obstet Gynecol. 1966 Jun 15;95(4):474–478. doi: 10.1016/0002-9378(66)90137-2. [DOI] [PubMed] [Google Scholar]
  16. Taymor M. L., Rizkallah T. H. Progestogen-estrogen therapy in the menopause. A double blind study. Am J Obstet Gynecol. 1967 Feb 15;97(4):460–464. doi: 10.1016/0002-9378(67)90557-1. [DOI] [PubMed] [Google Scholar]
  17. Wallach S., Henneman P. H. Prolonged estrogen therapy in postmenopausal women. J Am Med Assoc. 1959 Nov 21;171(12):1637–1642. [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES